Treatment of young people with antipsychotic medications in the United States

JAMA Psychiatry

Volumn 72, Issue 9, 2015, Pages 867-874

  Olfson, Mark ^a,b   King, Marissa ^c   Schoenbaum, Michael ^d  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c YALE SCHOOL OF MANAGEMENT   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CHILD; CHILDHOOD; CONTROLLED STUDY; DATA EXTRACTION; DEPRESSION; DESCRIPTIVE RESEARCH; DISRUPTIVE BEHAVIOR; DRUG DATABASE; FEMALE; GROUPS BY AGE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MENTAL DISEASE; MENTAL PATIENT; MOOD DISORDER; PHARMACY; PRESCHOOL CHILD; PRESCRIPTION; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SCHOOL CHILD; UNITED STATES; YOUNG ADULT; AGE DISTRIBUTION; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD PSYCHIATRY; CLINICAL PRACTICE; COHORT ANALYSIS; DEPRESSIVE DISORDER; FACTUAL DATABASE; INFANT; INTELLECTUAL DISABILITY; LONGITUDINAL STUDY; PSYCHIATRY; SEX RATIO; STATISTICS AND NUMERICAL DATA; TRENDS;

ADOLESCENT; ADOLESCENT PSYCHIATRY; AGE DISTRIBUTION; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD; CHILD PSYCHIATRY; CHILD, PRESCHOOL; COHORT STUDIES; DATABASES, FACTUAL; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFANT; INTELLECTUAL DISABILITY; LONGITUDINAL STUDIES; MALE; PRACTICE PATTERNS, PHYSICIANS'; PSYCHIATRY; PSYCHOTHERAPY; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; UNITED STATES; YOUNG ADULT;

EID: 84940969858     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.0500     Document Type: Article

References (49)

1. Olfson M, Blanco C, Wang S, Laje G, Correll CU. National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry. 2014;71(1):81-90.
2. Findling RL, Nyilas M, Fornes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441-1451.
3. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164(10):1547-1556.
4. Findling RL, Robb A, NyilasM, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165(11):1432-1441.
5. McCracken JT, McGough J, Shah B, et al; Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-321.
6. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119.
7. Matone M, Localio R, Huang YS, dosReis S, Feudtner C, Rubin D. The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: A national study of US Medicaid-enrolled children. Health Serv Res. 2012;47(5):1836-1860.
8. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247-1256.
9. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20 (2):177-184.
10. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D.Weight gain in antipsychotic-naive patients: A review and meta-analysis. Psychol Med. 2010;40(2):187-200.
11. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773.
12. Kreider AR, Matone M, Bellonci C, et al. Growth in the concurrent use of antipsychotics with other psychotropic medications in Medicaid-enrolled children. J Am Acad Child Adolesc Psychiatry. 2014; 53(9):960-970.e2.
13. DeHert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU.Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011; 26(3):144-158.
14. Bartelink IH, Rademaker CMA, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45(11):1077-1097.
15. Costa LG, Steardo L, Cuomo V. Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: Experimental and clinical aspects. Pharmacol Rev. 2004;56(1): 103-147.
16. Moran-Gates T, Grady C, Shik Park Y, Baldessarini RJ, Tarazi FI. Effects of risperidone on dopamine receptor subtypes in developing rat brain. Eur Neuropsychopharmacol. 2007;17(6-7): 448-455.
17. Choi YK, Moran-Gates T, Gardner MP, Tarazi FI. Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. Eur Neuropsychopharmacol. 2010;20(3):187-194.
18. Mandell DJ, Unis A, Sackett GP. Post-drug consequences of chronic atypical antipsychotic drug administration on the ability to adjust behavior based on feedback in young monkeys. Psychopharmacology (Berl). 2011;215(2):345-352.
19. Bardgett ME, Franks-Henry JM, Colemire KR, et al. Adult rats treated with risperidone during development are hyperactive. Exp Clin Psychopharmacol. 2013;21(3):259-267.
20. Gleason MM, Egger HL, Emslie GJ, et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1532-1572.
21. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770-w781. doi:10.1377/hlthaff.28.5.w770.
22. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord. 2007;10(4):335-342.
23. Penfold RB, Stewart C, Hunkeler EM, et al. Use of antipsychotic medications in pediatric populations: What do the data say [published correction appears in Curr Psychiatry Rep. 2014;16(2):432]? Curr Psychiatry Rep. 2013;15(12):426.
24. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19(9):629-635.
25. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9-20.
26. Agency for Healthcare Research and Quality. MEPS-HC panel design and data collection process. http://meps.ahrq.gov/survey-comp/hc-data-collection.jsp. Accessed January 10, 2015.
27. Pathak P, West D, Martin BC, Helm ME, Henderson C. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61(2):123-129.
28. Zito JM, Safer DJ, de Jong-van den Berg LT, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;2(1):26.
29. Murphy AL, Gardner DM, Cooke C, Kisely S, Hughes J, Kutcher SP. Prescribing trends of antipsychotics in youth receiving income assistance: Results from a retrospective population database study. BMC Psychiatry. 2013;13:198.
30. Moffitt TE. Adolescence-limited and life-course-persistent antisocial behavior: A developmental taxonomy. Psychol Rev. 1993;100 (4):674-701.
31. Snyder HN. Arrest in the United States, 1990-2010. US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. NJC 239423. http://www.bjs.gov/content/pub/pdf/aus9010.pdf Published October 2012. Accessed January 12, 2015.
32. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL; Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159(8):1337-1346.
33. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B; Risperidone Disruptive Behavior Study Group. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry. 2004;161(4): 677-684.
34. Monahan KC, Steinberg L, Cauffman E, Mulvey EP. Trajectories of antisocial behavior and psychosocial maturity from adolescence to young adulthood. Dev Psychol. 2009;45(6):1654-1668.
35. Steinberg L. A social neuroscience perspective on adolescent risk-taking. Dev Rev. 2008;28(1):78-106.
36. Pedersen CB, Mors O, Bertelsen A, et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry. 2014;71(5):573-581.
37. Kuehner C. Gender differences in unipolar depression: An update of epidemiological findings and possible explanations. Acta Psychiatr Scand. 2003;108(3):163-174.
38. Freeman VG, Rathore SS, Weinfurt KP, Schulman KA, Sulmasy DP. Lying for patients: physician deception of third-party payers. Arch Intern Med. 1999;159(19):2263-2270.
39. Anderson SL, Vande Griend JP. Quetiapine for insomnia: A review of the literature. Am J Health Syst Pharm. 2014;71(5):394-402.
40. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M.Management of psychiatric disorders in children and adolescentswith atypical antipsychotics: A systematic review of published clinical trials. Eur Child Adolesc Psychiatry. 2007;16(2):104-120.
41. Aman MG, Bukstein OG, Gadow KD, et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J AmAcad Child Adolesc Psychiatry. 2014;53(1):47-60.e1.
42. Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in US adolescents: Results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010; 49(10):980-989.
43. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: Ameta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9): 980-991.
44. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review andmeta-analysis. JAMA. 2011;306(12):1359-1369.
45. Eyberg SM, Nelson MM, Boggs SR. Evidence-based psychosocial treatments for children and adolescents with disruptive behavior. J Clin Child Adolesc Psychol. 2008;37(1):215-237.
46. David-Ferdon C, Kaslow NJ. Evidence-based psychosocial treatments for child and adolescent depression. J Clin Child Adolesc Psychol. 2008;37 (1):62-104.
47. March J, Silva S, Petrycki S, et al; Treatment for AdolescentsWith Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for AdolescentsWith Depression Study (TADS) randomized controlled trial. JAMA. 2004; 292(7):807-820.
48. Silverman WK, Pina AA, Viswesvaran C. Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents. J Clin Child Adolesc Psychol. 2008;37(1):105-130.
49. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.